Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04646044
Other study ID # 20-214-34
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 13, 2020
Est. completion date May 18, 2021

Study information

Verified date March 2024
Source Nektar Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 18, 2021
Est. primary completion date May 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patients, age 18 years or older on the day of signing the informed consent form. - Agrees to admission to an in-patient facility for monitoring from Days 1 to 8, inclusive. - Symptoms of mild illness with COVID-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious COVID-19. - Laboratory confirmed SARS-CoV-2 infection within 4 days prior to the screening visit or during the 7-day screening period. - Respiratory rate < 20 breaths per minute, heart rate < 90 beats per minute (bpm). - Oxygen saturation by pulse oximetry > 93% on room air. - Body mass index < 35 kg/m2. - Estimated glomerular filtration rate (eGFR) = 30 mL/min. - Alanine transaminase (ALT) or aspartate transaminase (AST) < 2 x upper limit of normal (ULN) and total bilirubin < 1.5 x ULN. - Agrees to not participate in another clinical trial for the treatment of COVID-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the Investigator. Exclusion Criteria: - Shortness of breath, hypoxia, or signs of serious lower airway disease. - C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) > 1.5 x ULN. - D-dimer or ferritin > 1.5 x ULN. - Imminently requiring, or currently on, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). - Systolic blood pressure < 90 mm Hg or diastolic blood pressure < 60 mm Hg. - Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS)/shock. - Known cardiovascular history, including unstable or deteriorating cardiac disease. - Autoimmune disease. - History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically significant venous or non-cerebrovascular accident/transient ischemic attack arterial thromboembolic event. - Central nervous system disease or dysfunction. - Requirement for > 2 anti-hypertensive medications. - Unwilling to refrain from alcohol consumption from Day 1 of admission to the in-patient facility until discharge from the facility. - Adrenal insufficiency. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bempegaldesleukin
Administered as an intravenous infusion
Standard of Care
Standard of Care Treatment for COVID-19 Infection
Other:
Placebo
Administered as an intravenous infusion

Locations

Country Name City State
United States A G A Clinical Trials - HyperCore - PPDS Hialeah Florida
United States New Generation Medical Research Hialeah Florida
United States SMS Clinical Research, LLC Mesquite Texas
United States Clinical Site Partners - Winter Park - HyperCore -PPDS Winter Park Florida

Sponsors (1)

Lead Sponsor Collaborator
Nektar Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC of Bempegaldesleukin [Pharmacokinetic Parameter]. Area under the serum concentration-time curve (AUC) of bempegaldesleukin calculated from time 0 to 168 hours. Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.
Primary Cmax of Bempegaldesleukin [Pharmacokinetic Parameter]. Maximum observed serum concentration (Cmax) of bempegaldesleukin. Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.
Primary Tmax of Bempegaldesleukin [Pharmacokinetic Parameter]. Time to maximum concentration of bempegaldesleukin. Cmax = maximum concentration. Tmax = time to maximum concentration. Day 1: Predose, 0.5, 24, 48, 72, 120, and 168 hours post dose.
Primary Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] Safety and Tolerability of bempegaldesleukin (starting at dose 0.00075 mg/kg) in combination with SOC was evaluated by incidence of Treatment-Emergent Adverse Events of Any Grade, Grade 3-4, and Grade 5 (Death). Safety and tolerability were evaluated from baseline up to approximately 30 days.
Primary Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) Dose finding for this study was based on the assessment of DLT of bempegaldesleukin dose levels. Number and percentage of patients with any DLT were summarized by bempegaldesleukin dose level in bempegaldesleukin plus SOC treatment groups [0.00075 mg/kg, N=5; 0.0015 mg/kg, N=5; and 0.003 mg/kg, N=5] and placebo plus SOC (N=15).
Adverse events related to study drug(s) that were defined as DLTs included the following:
Any Grade = 3 drug-related AE.
Any Grade = 3 drug-related laboratory abnormality that was clinically significant per the Investigator.
Respiratory compromise or other virus-related AE attributed to worsening COVID-19, such as severe hypoxia, cyanosis, or chest pain/pressure.
The event was considered a DLT if it was confirmed to be at least possibly related to study drug, met any of the above definitions, and was confirmed to have occurred in a patient treated with bempegaldesleukin.
The DLT evaluation period was up to approximately 7 days following the bempegaldesleukin treatment.
Primary Percent Change From Baseline for Absolute Lymphocyte Count (ALC) by Dose/Arm. To assess the effect of bempegaldesleukin on the time course and extent of changes in absolute lymphocyte counts (ALC). Data are reported by dose and arm for Day 8 compared to baseline. ALC was evaluated from baseline up to 7 days (Day 8) following the study drug administration.
Secondary Percentage of Patients Who Require Supplemental Oxygen. The percentage of patients requiring supplemental oxygen was evaluated as part of disease measurements to assess efficacy.
No patient in the study required supplemental oxygen.
From baseline, following the administration of study drug approximately up to 30 days.
Secondary Change From Baseline on the Daily Collection World Health Organization (WHO) Clinical Progression Scale, an 11-point Clinical Status Ordinal Scale. The WHO Clinical Progression Scale scores and descriptors are as follows: 0- Uninfected; no viral RNA detected; 1- Asymptomatic; viral RNA detected; 2- Symptomatic; independent; 3- Symptomatic; assistance needed; 4- Hospitalized, no oxygen therapy(a); 5- Hospitalized; oxygen by mask or nasal prongs ; 6- Hospitalized; oxygen by non-invasive ventilation or high-flow; 7- Intubation and mechanical ventilation, PaO2/FiO2 = 150 or SpO2/FiO2 = 200; 8- Mechanical ventilation, PaO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors; 9- Mechanical ventilation, PaO2/FiO2 < 150 and vasopressors, dialysis, or ECMO; 10- Death. The data are reported for Day 8 by arm. There were no scores rated 3 and higher per this scale at any timepoint.
Abbreviations: ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; PaO2 = partial pressure of arterial oxygen; SpO2 = oxygen saturation
(a) If hospitalized for isolation only, record status as for ambulatory patient.
Source: WHO 2020.
From baseline up to 7 days (Day 8) following the study drug administration.
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure